{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T08:07:58Z","timestamp":1790755678435,"version":"4.1.0"},"reference-count":44,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T00:00:00Z","timestamp":1688947200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Prothya Biosolutions","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Dutch Prinses Beatrix Fonds","award":["W.OR21-05"],"award-info":[{"award-number":["W.OR21-05"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,6,22]]},"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>For idiopathic inflammatory myopathies (IIM) (\u2018myositis\u2019) standard initial treatment is high-dosed glucocorticoids, which results in relatively slow improvement of muscle strength. Early immunosuppression or modulation by intensive treatment (\u2018hit-early, hit-hard\u2019) may induce faster reduction of disease activity and prevent chronic disability due to disease-induced structural muscle damage. Intravenous immunoglobulin (IVIg) in addition to standard glucocorticoid treatment may be promising in this regard as was shown in various studies: add-on IVIg improved symptoms and muscle strength in refractory myositis patients and monotherapy IVIg improved outcomes after 9 weeks, in about half of treatment-naive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Hypothesis<\/jats:title>\n                    <jats:p>We hypothesise that early add-on IVIg leads to a greater clinical response after 12 weeks in patients with newly diagnosed myositis, in comparison to prednisone monotherapy. Second, we expect that early treatment with add-on IVIg leads to a faster time to improvement and sustained positive effects on multiple secondary outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Time Is Muscle trial is a phase-2 double-blind placebo-controlled randomised trial. Forty-eight patients with IIM will be treated with IVIg or placebo at baseline (within 1 week after diagnosis) and after 4 and 8 weeks, in addition to standard therapy with prednisone. The primary outcome is the Total Improvement Score (TIS) of the myositis response criteria at 12 weeks. At baseline, and after 4, 8, 12, 26 and 52 weeks, relevant secondary outcomes will be assessed, including time to moderate improvement (TIS\u226540), mean daily prednisone dosage, physical activity, health-related quality of life, fatigue and MRI muscle imaging parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>Ethical approval was obtained from the medical ethics committee of the Academic Medical Centre, University of Amsterdam, the Netherlands (2020_180; including a first amendment approval at the 12 April 2023; A2020_180_0001). The results will be distributed through conference presentations and peer-reviewed publications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EU Clinical trials register (2020-001710-37).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-067435","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T13:08:14Z","timestamp":1688994494000},"page":"e067435","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct03092180","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9369-1127","authenticated-orcid":false,"given":"Renske G","family":"Kamperman","sequence":"first","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes A","family":"Bogaards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC - Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne W","family":"Evers","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9106-0508","authenticated-orcid":false,"given":"Hannah A W","family":"Walter","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"de Visser","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corianne","family":"de Borgie","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam University Medical Centre, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jantine C A","family":"Colen - de Koning","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Amsterdam UMC - Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camiel","family":"Verhamme","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Maas","sequence":"additional","affiliation":[{"name":"Department of Radiology and Nuclear Medicine, Amsterdam UMC - Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Eftimov","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo N","family":"van Schaik","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"},{"name":"Department of Neurology, Sanquin Blood Supply Foundation, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J","family":"van der Kooi","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost","family":"Raaphorst","sequence":"additional","affiliation":[{"name":"Department of Neurology and Clinical Neurophysiology, Amsterdam UMC Locatie AMC, University of Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2023,7,10]]},"reference":[{"key":"2025121408391048000_13.7.e067435.1","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"European League against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory Myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121408391048000_13.7.e067435.2","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000855"},{"key":"2025121408391048000_13.7.e067435.3","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary Myositis centre","volume":"60","author":"Loarce-Martos","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025121408391048000_13.7.e067435.4","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-012-0249-3"},{"key":"2025121408391048000_13.7.e067435.5","first-page":"2230","article-title":"Polymyositis and dermatomyositis: short term and longterm outcome, and predictive factors of prognosis","volume":"28","author":"Marie","year":"2001","journal-title":"J Rheumatol"},{"key":"2025121408391048000_13.7.e067435.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2010.03.011"},{"key":"2025121408391048000_13.7.e067435.7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00415-014-7313-z","article-title":"Long-term follow-up of 62 patients with Myositis","volume":"261","author":"van de Vlekkert","year":"2014","journal-title":"J Neurol"},{"key":"2025121408391048000_13.7.e067435.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201612"},{"key":"2025121408391048000_13.7.e067435.9","first-page":"588","article-title":"Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis","volume":"27","author":"Jing","year":"2008","journal-title":"Chinese J Geriatr"},{"key":"2025121408391048000_13.7.e067435.10","first-page":"1092","article-title":"Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients","volume":"21","author":"Cherin","year":"1994","journal-title":"J Rheumatol"},{"key":"2025121408391048000_13.7.e067435.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312303292704"},{"key":"2025121408391048000_13.7.e067435.12","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa2117912","article-title":"Trial of intravenous immune globulin in dermatomyositis","volume":"387","author":"Aggarwal","year":"2022","journal-title":"N Engl J Med"},{"key":"2025121408391048000_13.7.e067435.13","doi-asserted-by":"publisher","DOI":"10.1007\/BF01540896"},{"key":"2025121408391048000_13.7.e067435.14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1506163"},{"key":"2025121408391048000_13.7.e067435.15","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102997","article-title":"Efficacy and safety of intravenous and subcutaneous immunoglobulin therapy in idiopathic inflammatory myopathy: A systematic review and meta-analysis","volume":"21","author":"Goswami","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2025121408391048000_13.7.e067435.16","doi-asserted-by":"publisher","DOI":"10.3109\/s10165-011-0534-4"},{"key":"2025121408391048000_13.7.e067435.17","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)90009-M"},{"key":"2025121408391048000_13.7.e067435.18","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/rheumatology\/keaa459","article-title":"Intravenous Immunoglobulins as first-line treatment in idiopathic inflammatory Myopathies: a pilot study","volume":"60","author":"Lim","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2025121408391048000_13.7.e067435.19","first-page":"588","article-title":"Efficacy and safety of the combined treatment with intravenous immunoglobulin and oral glucocorticoid in the elderly with dermatomyositis","volume":"27","author":"Tian","year":"2008","journal-title":"Chin J Geriatr"},{"key":"2025121408391048000_13.7.e067435.20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.3.323"},{"key":"2025121408391048000_13.7.e067435.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61930-2"},{"key":"2025121408391048000_13.7.e067435.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.180353"},{"key":"2025121408391048000_13.7.e067435.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-150-10-200905190-00004"},{"key":"2025121408391048000_13.7.e067435.24","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.42"},{"key":"2025121408391048000_13.7.e067435.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053594","article-title":"Optimisation of diagnostic accuracy in idioPathic inflammaTory Myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of Multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy","volume":"11","author":"Walter","year":"2021","journal-title":"BMJ Open"},{"key":"2025121408391048000_13.7.e067435.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2019.10.005"},{"key":"2025121408391048000_13.7.e067435.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2004.02.006"},{"key":"2025121408391048000_13.7.e067435.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2017.09.016"},{"key":"2025121408391048000_13.7.e067435.29","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40674-018-0106-2","article-title":"Current treatment for Myositis","volume":"4","author":"Barsotti","year":"2018","journal-title":"Curr Treatm Opt Rheumatol"},{"key":"2025121408391048000_13.7.e067435.30","unstructured":"Castor electronic data capture. 2019. Available: https:\/\/castoredc.com"},{"key":"2025121408391048000_13.7.e067435.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211400"},{"key":"2025121408391048000_13.7.e067435.32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/art.40064","article-title":"2016 American college of rheumatology\/European League against rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an international Myositis assessment and clinical studies group\/Paediatric rheumatology International trials Organisation collaborative initiative","volume":"69","author":"Aggarwal","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121408391048000_13.7.e067435.33","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","article-title":"Update on outcome assessment in Myositis","volume":"14","author":"Rider","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2025121408391048000_13.7.e067435.34","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","article-title":"EQ-5D and the Euroqol group: past, present and future","volume":"15","author":"Devlin","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"2025121408391048000_13.7.e067435.35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039198","article-title":"Validity of six activity monitors in chronic obstructive pulmonary disease: a comparison with indirect Calorimetry","volume":"7","author":"Van Remoortel","year":"2012","journal-title":"PLoS One"},{"key":"2025121408391048000_13.7.e067435.36","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1093\/rheumatology\/keab236","article-title":"Reliability, validity and responsiveness of physical activity monitors in patients with inflammatory myopathy","volume":"60","author":"Rockette-Wagner","year":"2021","journal-title":"Rheumatology"},{"key":"2025121408391048000_13.7.e067435.37","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.11.7113"},{"key":"2025121408391048000_13.7.e067435.38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.semarthrit.2016.11.001","article-title":"The role of magnetic resonance imaging techniques in evaluation and management of the idiopathic inflammatory Myopathies","volume":"46","author":"Day","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"2025121408391048000_13.7.e067435.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202915"},{"key":"2025121408391048000_13.7.e067435.40","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2012-304670"},{"key":"2025121408391048000_13.7.e067435.41","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the cutaneous disease area and severity index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"2025121408391048000_13.7.e067435.42","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05083-1","article-title":"Intravenous immunoglobulin and intravenous methylprednisolone as optimal induction treatment in chronic inflammatory Demyelinating Polyradiculoneuropathy: protocol of an international, randomised, double-blind, placebo-controlled trial (OPTIC)","volume":"22","author":"Bus","year":"2021","journal-title":"Trials"},{"key":"2025121408391048000_13.7.e067435.43","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","article-title":"The iMTA productivity cost questionnaire: A standardized instrument for measuring and valuing health-related productivity losses","volume":"18","author":"Bouwmans","year":"2015","journal-title":"Value Health"},{"key":"2025121408391048000_13.7.e067435.44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23084301","article-title":"Pathophysiological mechanisms and treatment of dermatomyositis and immune mediated necrotizing Myopathies: A focused review","volume":"23","author":"Kamperman","year":"2022","journal-title":"Int J Mol Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-067435","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T16:39:20Z","timestamp":1765730360000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-067435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":44,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7,10]]},"published-print":{"date-parts":[[2023,7]]}},"alternative-id":["10.1136\/bmjopen-2022-067435"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-067435","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}